Inve US ▾
ICICUI

ICU Medical (ICUI) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

ICU Medical Q2 FY26 — Strong Organic Growth and Raised Full-Year Guidance

ICU Medical delivered a strong second quarter, driven by robust organic growth in its core Consumables and IV Systems businesses, leading to raised full-year adjusted EBITDA and EPS guidance. The company made significant progress on debt reduction, nearing its leverage target, and continues to advance its strategic vision for a comprehensive infusion therapy portfolio, despite ongoing macroeconomic headwinds from currency and tariffs. Innovation in new product cycles and operational efficiencies are expected to drive future margin expansion and predictable revenue growth.

Highlights

5

  • Total company organic revenue growth of 6% in Q2 FY26.

  • Adjusted EBITDA improved to $110 million, reflecting 10% growth year-over-year.

  • Adjusted EPS increased 13% to $2.37 compared to $2.10 last year.

  • Strong free cash flow of $62 million, enabling $50 million debt repayment and reducing net leverage to 2.3x.

  • Full-year adjusted EBITDA guidance raised to $415 million-$435 million and adjusted EPS guidance raised to $8.60-$9.00.

Concerns

4

  • Reported revenue growth was only 1% due to the deconsolidation of the IV Solutions JV and OEM wind down.

  • Vital Care segment decreased 4% organically and 32% reported due to JV deconsolidation.

  • Continued negative impact from currency fluctuations (Costa Rican Colon, Mexican Peso, Japanese Yen) and tariffs, totaling $90 million-$100 million annually.

  • Higher logistics expense from elevated diesel costs impacted gross margins.

Guidance & targets

CategoryTargetConfidence
Full-year Adjusted EBITDA
$415M-$435M
high materiality
High
Full-year Adjusted EPS
$8.60-$9.00 per share
high materiality
High
Full-year Adjusted Gross Margin
around 41.5%
medium materiality
High
Consumables Business Organic Growth
mid-single-digit growth
medium materiality
High
IV Systems Organic Growth
at or above 6% rate
medium materiality
High
Vital Care Business Performance
down slightly for the year
low materiality
Medium
Net Leverage Ratio
approximately 2x
high materiality
High
Full-year Adjusted Operating Expenses
approximately 25% of revenue
medium materiality
High
Full-year Net Interest Expense
$65M
medium materiality
High
Full-year Adjusted Tax Rate
25%
medium materiality
High
Full-year Diluted Shares Outstanding
25.2 million
medium materiality
High
Full-year JV Earnings Contribution
breakeven or a small loss
low materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Total Company
Reported results impacted by mid-2025 creation of Otsuka ICU Medical JV and deconsolidation of IV Solutions.
Organic growth: 6%
$548M1% reported——
Consumables
Growth was balanced across all 4 product families and improved year-over-year. Mid-single-digit growth expected for the remainder of the year.
Organic growth: 5%Record absolute sales
—6% reported——
IV Systems
Dedicated sets were strong, offset by declines in OEM revenues. Some earlier-than-expected installations occurred. Organic growth expected to continue at or above 6% rate for Q3.
Organic growth: 12%Record quarter in pumps
—13% reported——
Vital Care
Decrease due to deconsolidation of IV Solutions. Sequential improvement observed, with stability expected for the balance of the year and down slightly for the full year.
Organic decrease: 4%
—decreased 32% reported——

ICUI operating KPIs by quarter

ICUI operating KPIs stated on its earnings calls, by fiscal quarter
KPI Mar 2026 Q1 FY26This call Jun 2026 Q2 FY26Change vs prior quarter
Capital expenditures General maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US
$11M During the quarter, we invested $9 million of cash spend for quality system and product-related remediation activities, $17 million on restructuring and integration and $11 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US Source: earnings call transcript
$19M During the quarter, we invested $11 million of cash spend for quality system and product-related remediation activities, $11 million on restructuring and integration and $19 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US Source: earnings call transcript
+72.7%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

Otsuka IV Solutions production and technology $0.5B investment

Otsuka, as the joint venture partner, announced a $0.5 billion investment into IV Solutions production. A groundbreaking ceremony for the first and largest greenfield IV Solutions production site in the U.S. in this century is scheduled for August 24 on adjacent land to the current facility.

Risks & headwinds

Currency fluctuations Ongoing

Negative impact of approximately $60 million over the last 4 years

Mitigation:Focus on controllable items like synergy realization, incremental pricing, and product mix to offset impact.

Tariff burden Ongoing

$30M-$40M annual range

Mitigation:Focus on controllable items like synergy realization, incremental pricing, and product mix to offset impact. Lower Section 122 tariffs in Q2 helped.

Higher logistics expense Q2 FY26

Impacted Q2 gross margin

Mitigation:Offset by lower tariff expense and accelerated synergy capture.

OEM wind down Remainder of FY26

1-2 point drag on IV Systems segment

Mitigation:Offset by strong performance in other IV Systems lines and competitive wins.

FDA approval delays Expected resubmission this year

Medfusion 5000 syringe pump resubmission delayed from initial expectations

Mitigation:Prioritizing resources for additional verification testing to expedite resubmission.

Macroeconomic volatility FY26

Inflation, currency, and interest rates in line with today's levels assumed in guidance

Mitigation:Guidance assumes stable macroeconomic environment and latest forecasts for oil/diesel prices and tariff policies.

What to watch in Q3 FY26

Medfusion 5000 FDA resubmission

this year
Current Substantial progress on verification testing
Target Amended package submitted to FDA

Why it matters

FDA approval is critical for unlocking a large upgrade base and competitive wins for this syringe pump.

The biggest update since the last call is that we made substantial progress on the additional verification testing required by FDA for the Medfusion 5000 syringe pump and believe an amended package will go back into the FDA this year.

Find out whether ICUI delivers this. Inve re-checks your case every morning.

Q&A highlights

Is the 12% growth in Infusion Systems due to an uptick in the replacement cycle or competitive wins?

The strong growth in Infusion Systems was primarily driven by competitive wins from the previous year and earlier in the current year, along with some upgrades to existing customers. The major upgrade cycle has not yet started in earnest.

“Some of it is upgrades to existing customers. The majority is competitive. I certainly, we don't want to. There is some -- always some upgrading going on.”

asked by Jayson Bedford · answered by Vivek Jain

2 min read 6 chapters

Detailed narrative

Q2 Performance and Full-Year Outlook

ICU Medical reported Q2 FY26 revenue of $548 million, achieving 6% organic growth, though reported growth was 1% due to the deconsolidation of the IV Solutions JV. Adjusted gross margins reached 41%, and adjusted EBITDA improved to $110 million, representing 10% year-over-year growth. Adjusted EPS was $2.37, up 13% from the prior year. The company raised its full-year adjusted EBITDA guidance to $415 million-$435 million and adjusted EPS guidance to $8.60-$9.00, reflecting confidence in continued business momentum.

Business Segment Highlights

The Consumables business recorded a record quarter with 6% reported and 5% organic growth, balanced across all four product families. IV Systems also had a record quarter in pumps, growing 13% reported and 12% organically, driven by earlier-than-expected installations and competitive wins. Vital Care decreased 4% organically and 32% reported due to the JV deconsolidation, but sequential improvement is expected, with the business projected to be down slightly for the full year.

Strategic Vision and Innovation

ICU Medical is committed to its mission of creating a comprehensive infusion therapy company. The company is at the beginning of new product cycles across its differentiated lines, including the LifeShield, Plum Duo, and Solo family of products in Infusion Systems. Significant progress has been made on the Medfusion 5000 syringe pump FDA resubmission, with an amended package expected to be submitted this year. The long-term vision includes connecting the home care CADD environment into a common software framework.

IV Solutions Joint Venture and Manufacturing Investment

The IV Solutions joint venture partner, Otsuka, announced a $0.5 billion investment to bring PVC-free products and production technologies to the U.S. market. A groundbreaking ceremony for a new greenfield IV Solutions production site in the U.S. is scheduled for August 24. This investment is seen as a win-win for U.S. customers, providing new offerings alongside ICU Medical's pump and consumables innovations, despite the JV's revenues no longer flowing through ICU Medical's income statement.

Capital Allocation and Leverage

Strong organic free cash flow, combined with tariff refunds, allowed ICU Medical to repay $50 million of debt in Q2, reducing its net leverage ratio to 2.3x. The company is on track to hit its target of approximately 2x leverage by year-end. Management emphasized protecting the share base and minimal external M&A needs, focusing on organic innovation and transferring value from debt to equity. Reduced cash consumption from restructuring and remediation work is a key driver for achieving leverage targets.

Macroeconomic Headwinds and Mitigation

ICU Medical continues to face headwinds from tariffs, which are in the $30 million-$40 million annual range, and adverse currency movements, particularly the Costa Rican Colon, Mexican Peso, and Japanese Yen, which have had a negative impact of approximately $60 million over the last four years. Higher logistics expenses due to elevated diesel costs also impacted gross margins. The company is focusing on controllable items like synergy realization, incremental pricing, and product mix to achieve its target of 2 percentage points of additional gross margin.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.